Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Common Toxicities of CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer

September 19th 2023

The panel explains how treatment experience with CDK4/6 inhibitors varies for patients with HR+/HER- breast cancer, and which agents are best tolerated.

Considerations for Use of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

September 19th 2023

Dr Naomi Dempsey explains how she decides on an appropriate CDK4/6 inhibitor for patients receiving first-line treatment for metastatic HR+/HER- breast cancer.

Dr West on Adjuvant Endocrine Therapy Plus a CDK4/6 Inhibitor in Early-Stage Breast Cancer

September 18th 2023

Malinda West, MD, MS, discusses the use of adjuvant endocrine therapy in combination with CDK4/6 inhibitors in the treatment of patients with early-stage HER2-negative breast cancer.

Continued Research Underscores the Need to Explore New Approaches Across the Breast Cancer Armamentarium

September 15th 2023

Stephanie L. Graff, MD, expands on treatment options available for patients with premenopausal breast cancer who are trying to conceive, highlighting the POSITIVE trial in women with endocrine-responsive breast cancer.

Dr Phadke on the Benefit of Sacituzumab Govitecan in HR+/HER2– Breast Cancer

September 14th 2023

Sneha Phadke, DO, MPH, discusses the benefit associated with treatment consisting of the antibody drug conjugates sacituzumab govitecan in hormone receptor-positive/HER2-negative breast cancer.

Dr Sharifi on the Importance of ctDNA Testing in Breast Cancer

September 14th 2023

Marina Sharifi, MD, PhD, discusses the benefit of utilizing personalized and targeted therapy approaches in the treatment of patients with breast cancer.

Frontline CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

September 13th 2023

Naomi Dempsey, MD, reviews data on the use of CDK4/6 inhibitors for the frontline treatment of metastatic HR+/HER- breast cancer.

Monitoring and Treating Lymphedema in Patients With HR+/HER- Breast Cancer

September 13th 2023

Nadia Nocera Zachariah, MD, explains why early detection and monitoring of lymphedema is crucial in patients with HR+/HER- breast cancer, with technologies like prophylactic compression sleeves and nighttime compression systems showing promise in reducing negative impact on quality of life.

Dr Phadke on Sequencing ADCs in HR+/HER2– Breast Cancer

September 12th 2023

Sneha Phadke, DO, MPH, discusses sequencing treatment with antibody drug conjugates in hormone receptor-positive/HER2-negative breast cancer, as well as questions remaining within this space.

Case Presentation: A 72-Year-Old Woman With HR+/HER2- mBC

September 12th 2023

Virginia Kaklamani, MD, presents the case of a 47-year-old premenopausal woman diagnosed with HR+/HER2- metastatic breast cancer for discussion.

Overview of HR+/HER2- Metastatic Breast Cancer (mBC)

September 12th 2023

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, offer an overview of HR+/HER2- metastatic breast cancer and detail the standard-of-care first-line therapy options.

Dr Hamilton on the Benefit Derived From Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 8th 2023

Erika P. Hamilton, MD, discusses the benefit seen with adjuvant ribociclib in patients with hormone receptor-positive,HER2-negative breast cancer.

Updates in Adjuvant Therapy for HR+/HER- Breast Cancer From ASCO 2023: The NATALEE Trial

September 6th 2023

Dr Naomi Dempsey shares the study design, primary outcome data, and the 3-year invasive disease-free survival follow-up data from the NATALEE trial in HR+/HER2- breast cancer presented at ASCO 2023.

Helping Patients With HR+/HER2- Breast Cancer Access Abemaciclib

September 6th 2023

Experts explain the challenges patients with HR+/HER- breast cancer face in accessing abemaciclib for treatment and the options available such as patient assistance programs for high co-pays.

Dr Armaghani on the Investigation of De-Escalated Treatment Approaches in TNBC

September 5th 2023

Avan Armaghani,cdiscusses the feasibility of de-escalating treatment in triple-negative breast cancer, as well as planned or ongoing research investigating this approach in the neoadjuvant and metastatic settings.

Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

September 2nd 2023

Raymond Mailhot Vega, MD, MPH, delves into the rationale for exploring the outcomes of patients who underwent axillary surgery or sentinel lymph node biopsy, explained the implications of these findings, and detailed what eventual data from the phase 3 Alliance A011202 could mean for the breast cancer treatment paradigm.

Dr Quiroga on the Emergence of HER2-Low in Breast Cancer

September 1st 2023

Dionisia Quiroga, DO, PhD, discusses the emergence of the HER2-low categorization in breast cancer as well as current treatment options for patients with HER2-low disease.

Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer

September 1st 2023

Meghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.

Dr Gatti-Mays on Updated Biomarker Data From the NeoPACT Study in TNBC

August 31st 2023

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses updated biomarker data from the phase 2 NeoPACT trial of neoadjuvant chemoimmunotherapy in triple-negative breast cancer.

Considerations for Chemotherapy Dosing in Patients With HR+/HER- Breast Cancer

August 30th 2023

The panel discusses the importance of careful chemotherapy dosing and management of side effects for patients with HR+/HER- breast cancer, including the use of cooling and compression gloves to prevent peripheral neuropathy.